9.513 USD
-0.2 (-2.03%)
TLRY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TLRY have multiple concerns. While showing a medium growth rate, TLRY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- TLRY had negative earnings in the past year.
- TLRY had a negative operating cash flow in the past year.
- TLRY had negative earnings in each of the past 5 years.
- In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -100.42%, TLRY is doing worse than 78.42% of the companies in the same industry.
- TLRY's Return On Equity of -133.40% is on the low side compared to the rest of the industry. TLRY is outperformed by 68.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.42% | ||
| ROE | -133.4% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TLRY has a Gross Margin of 28.02%. This is comparable to the rest of the industry: TLRY outperforms 56.32% of its industry peers.
- TLRY's Gross Margin has improved in the last couple of years.
- TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
- TLRY has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for TLRY has been increased compared to 5 years ago.
- The debt/assets ratio for TLRY is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -1.39, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
- TLRY has a Altman-Z score (-1.39) which is in line with its industry peers.
- TLRY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
- TLRY's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. TLRY outperforms 46.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.39 |
ROIC/WACCN/A
WACC8.31%
2.3 Liquidity
- TLRY has a Current Ratio of 2.81. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
- TLRY has a Current ratio (2.81) which is in line with its industry peers.
- A Quick Ratio of 1.72 indicates that TLRY should not have too much problems paying its short term obligations.
- TLRY's Quick ratio of 1.72 is in line compared to the rest of the industry. TLRY outperforms 41.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.81 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
- The earnings per share for TLRY have decreased strongly by -379.00% in the last year.
- Looking at the last year, TLRY shows a small growth in Revenue. The Revenue has grown by 0.98% in the last year.
- Measured over the past years, TLRY shows a very strong growth in Revenue. The Revenue has been growing by 37.52% on average per year.
EPS 1Y (TTM)-379%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59%
Revenue 1Y (TTM)0.98%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%3.11%
3.2 Future
- TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.45% yearly.
- The Revenue is expected to grow by 4.41% on average over the next years.
EPS Next Y96.64%
EPS Next 2Y40.72%
EPS Next 3Y25.89%
EPS Next 5Y15.45%
Revenue Next Year3.92%
Revenue Next 2Y4.25%
Revenue Next 3Y3.91%
Revenue Next 5Y4.41%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, TLRY is valued a bit cheaper than 78.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 27.48 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as TLRY's earnings are expected to grow with 25.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.72%
EPS Next 3Y25.89%
5. Dividend
5.1 Amount
- No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TLRY (1/16/2026, 11:05:06 AM)
9.513
-0.2 (-2.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-08 2026-01-08/amc
Earnings (Next)04-06 2026-04-06/bmo
Inst Owners11.21%
Inst Owner Change-0.43%
Ins Owners0.35%
Ins Owner Change2.66%
Market Cap1.10B
Revenue(TTM)837.32M
Net Income(TTM)-2.11B
Analysts71.25
Price Target13.78 (44.85%)
Short Float %N/A
Short Ratio0.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.49%
Min EPS beat(2)-100.98%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-1374.81%
Min EPS beat(4)-5362.97%
Max EPS beat(4)100%
EPS beat(8)1
Avg EPS beat(8)-733.35%
EPS beat(12)2
Avg EPS beat(12)-748.47%
EPS beat(16)3
Avg EPS beat(16)-621.09%
Revenue beat(2)2
Avg Revenue beat(2)0.75%
Min Revenue beat(2)0.41%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-4.75%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)1.09%
Revenue beat(8)2
Avg Revenue beat(8)-5.24%
Revenue beat(12)3
Avg Revenue beat(12)-2.69%
Revenue beat(16)3
Avg Revenue beat(16)-3.19%
PT rev (1m)0%
PT rev (3m)1562.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-788.89%
EPS NY rev (1m)-913.34%
EPS NY rev (3m)-369.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.7 | ||
| P/tB | 1.37 | ||
| EV/EBITDA | 27.48 |
EPS(TTM)-14.37
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS7.22
BVpS13.62
TBVpS6.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.42% | ||
| ROE | -133.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.02% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 40.31% | ||
| Cap/Sales | 4.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.81 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | -1.39 |
F-Score3
WACC8.31%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-379%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59%
EPS Next Y96.64%
EPS Next 2Y40.72%
EPS Next 3Y25.89%
EPS Next 5Y15.45%
Revenue 1Y (TTM)0.98%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%3.11%
Revenue Next Year3.92%
Revenue Next 2Y4.25%
Revenue Next 3Y3.91%
Revenue Next 5Y4.41%
EBIT growth 1Y41.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.61%
EBIT Next 3Y28.42%
EBIT Next 5Y17.38%
FCF growth 1Y-53.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.64%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.
What is the valuation status for TLRY stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY) stock?
TILRAY BRANDS INC (TLRY) has a profitability rating of 1 / 10.